β-Glucan, a “Specific” Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)

J Immunol September 15, 1999, 163 (6) 3045-3052;Yan J Immunol 1999 — Article shows that beta glucan enhances tumor targeting by immune cells when used with certain antibodies. Article also describes beta glucan’s role in  (modifying) cancer tumor cells with an iC3b molecule causing immune cells to target those tumor cells which may otherwise not be attacked.  Read more…